Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events
- PMID: 17403173
- DOI: 10.1111/j.1542-4758.2007.00171.x
Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events
Abstract
Homocysteine is a risk factor for atherosclerosis in the general population, and serum homocysteine levels are almost universally elevated in chronic renal failure patients. When such patients are treated with dialysis, cardiovascular disease accounts for more than 50% of their mortality, which, in some proportion, may be pathophysiologically related to the elevated serum homocysteine levels. From April 2003 to March 2005, we conducted a 2-year, double-blind, randomized, placebo-controlled trial of 186 patients with end-stage kidney disease due to any cause, who were older than 18 years and stable on hemodialysis. Patients were assigned to receive either oral folic acid 10 mg 3 times a week immediately after every dialysis session under nurse supervision or an identical-appearing placebo for the entire study. On admission, plasma total homocysteine (tHcy) levels were above 13.9 micromol/L in 96.7% of patients (median 25.0 micromol/L, range 9.3-104.0 micromol/L). In the placebo group, tHcy levels remained elevated at 6, 12, and 24 months, while oral folate significantly decreased tHcy to a median value of 10.5 (2.8-20.3) micromol/L, (p<0.01). During the study, 38 patients (folic acid group 17 vs. placebo group 21; p=0.47) died from cardiovascular disease. Kaplan-Meier life table analysis dealing with the incidence of cardiovascular events, both fatal and nonfatal (myocardial infarction, arrhythmias, angina, heart failure, cerebrovascular accident), showed that 2 years of folic acid treatment and the lowering of the homocysteine blood levels had no effect on cardiovascular events (p=0.41; hazard ratio 1.24, 95% CI 0.74-2.10). However, the carotid artery intima-media wall thickness measured in a blinded fashion decreased from 1.94 +/- 0.59 mm to 1.67 +/- 0.38 mm (p<0.01) after 2 years of folate therapy. In this short-term study of uremic patients, 2 years of folic acid supplementation normalized the tHcy blood levels in 92.3% of patients but did not change the incidence of cardiovascular events compared with the control group. However, ultrasonography of the common carotid arteries performed at entry and 24 months later showed a significant decrease in intima-media thickness with folate supplementation. This suggests that early folate supplementation may benefit patients with chronic renal failure by preventing cardiovascular deterioration.
Similar articles
-
[The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].Acta Med Croatica. 2006 Jun;60(3):201-8. Acta Med Croatica. 2006. PMID: 16933832 Croatian.
-
Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.Blood Purif. 2006;24(4):379-86. doi: 10.1159/000093680. Epub 2006 Jun 1. Blood Purif. 2006. PMID: 16755160 Clinical Trial.
-
Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.J Am Coll Cardiol. 2006 Mar 21;47(6):1108-16. doi: 10.1016/j.jacc.2005.10.064. Epub 2006 Feb 23. J Am Coll Cardiol. 2006. PMID: 16545638 Clinical Trial.
-
Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.Semin Thromb Hemost. 2000;26(3):341-8. doi: 10.1055/s-2000-8101. Semin Thromb Hemost. 2000. PMID: 11011852 Review.
-
Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.Z Kardiol. 2004 Jun;93(6):439-53. doi: 10.1007/s00392-004-0075-3. Z Kardiol. 2004. PMID: 15252738 Review.
Cited by
-
Plasma Homocysteine Levels and Cardiovascular Events in Patients With End-Stage Renal Disease: A Systematic Review.Cureus. 2023 Jun 13;15(6):e40357. doi: 10.7759/cureus.40357. eCollection 2023 Jun. Cureus. 2023. PMID: 37456428 Free PMC article. Review.
-
Nutritional Approaches to Modulate Cardiovascular Disease Risk in Systemic Lupus Erythematosus: A Literature Review.Nutrients. 2023 Feb 19;15(4):1036. doi: 10.3390/nu15041036. Nutrients. 2023. PMID: 36839394 Free PMC article. Review.
-
Homocysteine-Lowering Interventions in Chronic Kidney Disease.J Res Pharm Pract. 2021 Dec 25;10(3):114-124. doi: 10.4103/jrpp.jrpp_75_21. eCollection 2021 Jul-Sep. J Res Pharm Pract. 2021. PMID: 35198504 Free PMC article. Review.
-
Comparing the Effect of Folic Acid and Pentoxifylline on Delaying Dialysis Initiation in Patients with Advanced Chronic Kidney Disease.Nutrients. 2019 Sep 12;11(9):2192. doi: 10.3390/nu11092192. Nutrients. 2019. PMID: 31547288 Free PMC article.
-
Functional iron deficiency in patients on hemodialysis: prevalence, nutritional assessment, and biomarkers of oxidative stress and inflammation.J Bras Nefrol. 2019 Oct-Dec;41(4):472-480. doi: 10.1590/2175-8239-JBN-2018-0092. J Bras Nefrol. 2019. PMID: 31441929 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous